JP2004516823A - タンパク質に対するホスホキナーゼ活性の定量のための方法 - Google Patents

タンパク質に対するホスホキナーゼ活性の定量のための方法 Download PDF

Info

Publication number
JP2004516823A
JP2004516823A JP2002530779A JP2002530779A JP2004516823A JP 2004516823 A JP2004516823 A JP 2004516823A JP 2002530779 A JP2002530779 A JP 2002530779A JP 2002530779 A JP2002530779 A JP 2002530779A JP 2004516823 A JP2004516823 A JP 2004516823A
Authority
JP
Japan
Prior art keywords
protein
phosphorylated
antibody
kinase
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002530779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516823A5 (https=
Inventor
ケヴィン ジェイ． レーガン、
エリック シェーフェー、
ジミン ワン、
Original Assignee
バイオソース インターナショナル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオソース インターナショナル filed Critical バイオソース インターナショナル
Publication of JP2004516823A publication Critical patent/JP2004516823A/ja
Publication of JP2004516823A5 publication Critical patent/JP2004516823A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2002530779A 2000-09-27 2001-09-27 タンパク質に対するホスホキナーゼ活性の定量のための方法 Withdrawn JP2004516823A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23562000P 2000-09-27 2000-09-27
PCT/US2001/030186 WO2002027017A2 (en) 2000-09-27 2001-09-27 Method for quantifying phosphokinase activity on proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006079226A Division JP2006225396A (ja) 2000-09-27 2006-03-22 タンパク質に対するホスホキナーゼ活性の定量のための方法

Publications (2)

Publication Number Publication Date
JP2004516823A true JP2004516823A (ja) 2004-06-10
JP2004516823A5 JP2004516823A5 (https=) 2005-04-28

Family

ID=22886277

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002530779A Withdrawn JP2004516823A (ja) 2000-09-27 2001-09-27 タンパク質に対するホスホキナーゼ活性の定量のための方法
JP2006079226A Pending JP2006225396A (ja) 2000-09-27 2006-03-22 タンパク質に対するホスホキナーゼ活性の定量のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006079226A Pending JP2006225396A (ja) 2000-09-27 2006-03-22 タンパク質に対するホスホキナーゼ活性の定量のための方法

Country Status (7)

Country Link
US (4) US20030162230A1 (https=)
EP (3) EP1328812B1 (https=)
JP (2) JP2004516823A (https=)
AT (1) ATE416385T1 (https=)
CA (1) CA2423979C (https=)
DE (1) DE60136840D1 (https=)
WO (1) WO2002027017A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531580A (ja) * 2015-07-13 2018-11-01 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
JP2019529336A (ja) * 2016-07-12 2019-10-17 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
JP2019207260A (ja) * 2013-12-27 2019-12-05 国立大学法人 東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
JP2019537727A (ja) * 2016-11-21 2019-12-26 ルール−ウニベルシタット ボーフム アルツハイマー病の鑑別診断のための複合アッセイ

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
GB0208104D0 (en) * 2002-04-09 2002-05-22 Univ Dundee Method
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7781173B2 (en) * 2003-09-25 2010-08-24 Life Technologies Corporation Homogeneous populations of molecules
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
EP1910828A4 (en) * 2005-07-01 2012-03-14 Univ St Louis PHOSPHOSPECTIVE CHEMOKIN RECEPTOR ANTIBODIES
WO2007133688A2 (en) * 2006-05-12 2007-11-22 Cell Signaling Technology, Inc. Reagents for the detection of tyrosine phosphorylation in brain ischemia signaling pathways
US20100160339A1 (en) * 2007-05-21 2010-06-24 Mayo Foundation For Medical Education And Research Treating pancreatitis
KR101612442B1 (ko) 2008-05-13 2016-04-15 삼성전자주식회사 컨텐츠 시청 제한 정보의 제공 및 이용을 위한 방법 및장치
US20130231305A1 (en) * 2010-03-29 2013-09-05 Medvet Science Pty. Ltd. Method of Modulating Protein 14-3-3 Functionality By Facilitating or Inhibiting Phosphorylation
US20170016900A1 (en) 2010-09-07 2017-01-19 Stephen G. Marx Kit for monitoring, detecting and staging gvhd
ES2692833T3 (es) * 2010-09-07 2018-12-05 Stephen G. Marx Kit para controlar, detectar y estadificar GVHD
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
AU2015240088B2 (en) * 2014-03-31 2021-07-22 Merck Patent Gmbh Method for detecting protein modifications using specific antibodies
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
AU2017225907B2 (en) * 2016-03-01 2023-11-23 Celosia Therapeutics Pty Ltd Use of phosphorylated tau and p38gamma to treat a neurological condition
WO2018127519A1 (en) 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
KR20200100726A (ko) * 2017-12-18 2020-08-26 예일 유니버시티 섬유증 치료용 화합물 및 조성물
MA53338A (fr) 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US11085935B2 (en) * 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP4028775A4 (en) 2019-09-10 2023-04-12 Washington University BLOOD-BASED TEST FOR DIAGNOSIS AND TREATMENT BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2354288C2 (de) 1973-10-30 1976-01-02 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Aminophenylalkyläthern
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JPH05126833A (ja) 1991-10-31 1993-05-21 Tosoh Corp チロシンキナ−ゼ活性の免疫化学的測定法及びそのキツト
ATE398176T1 (de) * 1991-12-06 2008-07-15 Max Planck Gesellschaft Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
ES2268684T3 (es) 1992-04-10 2007-03-16 Dana-Farber Cancer Institute, Inc. Inmunodeteccion de fosfoproteina especifica al estado de activacion.
DE69318420T2 (de) * 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
US6924361B1 (en) 1993-11-02 2005-08-02 Phosphoproteomics Llc Phosphopeptide-specific antibodies that are activity specific; methods of production and antibody uses
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
DK0737208T3 (da) * 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
US6348310B1 (en) * 1994-03-04 2002-02-19 Promega Corporation Quantitation of individual protein kinase activity
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
EP0772634B1 (en) * 1994-07-29 2003-03-12 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
US6001580A (en) * 1995-03-28 1999-12-14 Takeda Chemical Industries, Inc. Method for assaying ERK2 map kinase
AU753557B2 (en) * 1997-11-07 2002-10-24 Vasopharm Biotech Gmbh Antibodies against phosphorylated vasp (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use
DE69811724T2 (de) * 1997-12-05 2003-10-16 Pharmacia & Upjohn Co., Kalamazoo Fluoreszenz-basierte hts-(high throughput screening)assayverfahren für proteinkinase und phosphatase
GB9803399D0 (en) * 1998-02-19 1998-04-15 Imp Cancer Res Tech Protein kinase c
JP2000034300A (ja) * 1998-07-17 2000-02-02 Mitsubishi Chemicals Corp 抗リン酸化タウ蛋白質抗体及びそれを用いるアルツハイマー病の検出方法
US6309863B1 (en) 1999-01-25 2001-10-30 Brookhaven Science Associates Methods for generating phosphorylation site-specific immunological reagents
AU5604900A (en) * 1999-06-09 2000-12-28 Ljl Biosystems, Inc. Phosphorylation assays
EP1207395A4 (en) * 1999-08-04 2003-08-13 Med & Biological Lab Co Ltd METHOD FOR MEASURING KINASE ACTIVITY OR CYCLINE / CDK COMPLEX
DE60123752T2 (de) * 2000-01-24 2007-08-23 Innogenetics N.V. Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
US20030166016A1 (en) 2000-04-28 2003-09-04 Foster Barbara A. Assay methods for cyclin dependent kinases
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019207260A (ja) * 2013-12-27 2019-12-05 国立大学法人 東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
JP2018531580A (ja) * 2015-07-13 2018-11-01 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
JP2019529336A (ja) * 2016-07-12 2019-10-17 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
JP2019537727A (ja) * 2016-11-21 2019-12-26 ルール−ウニベルシタット ボーフム アルツハイマー病の鑑別診断のための複合アッセイ
JP7117476B2 (ja) 2016-11-21 2022-08-15 ベータセンス ゲーエムベーハー アルツハイマー病の鑑別診断のための複合アッセイ

Also Published As

Publication number Publication date
ATE416385T1 (de) 2008-12-15
EP2040078A1 (en) 2009-03-25
WO2002027017A3 (en) 2003-01-16
WO2002027017A2 (en) 2002-04-04
CA2423979C (en) 2012-03-06
EP2298814A2 (en) 2011-03-23
CA2423979A1 (en) 2002-04-04
US20110165588A1 (en) 2011-07-07
US20120135426A1 (en) 2012-05-31
US8114617B2 (en) 2012-02-14
EP1328812A2 (en) 2003-07-23
JP2006225396A (ja) 2006-08-31
EP1328812B1 (en) 2008-12-03
DE60136840D1 (de) 2009-01-15
US7888050B2 (en) 2011-02-15
US20090104628A1 (en) 2009-04-23
US20030162230A1 (en) 2003-08-28
EP2298814A3 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
CA2423979C (en) Method for quantifying phosphokinase activity on proteins
AU698975B2 (en) Kinase receptor activation assay
US5599681A (en) Activation-state-specific phosphoprotein immunodetection
Lamphere et al. Interaction between Cdc37 and Cdk4 in human cells
US5766863A (en) Kinase receptor activation assay
HK1008440B (en) Kinase receptor activation assay
Prieto-Echagüe et al. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1
US20110269161A1 (en) Methods, Compositions and Kits for High Throughput Kinase Activity Screening Using Mass Spectrometry and Stable Isotopes
JP4828752B2 (ja) サイクリン／ｃｄｋ複合体のリン酸化酵素活性測定方法
JP5283872B2 (ja) 腫瘍細胞に対する阻害剤の増殖抑制効果を評価する方法、及び腫瘍細胞の増殖を阻害する化合物をスクリーニングする方法
JPWO2001011367A1 (ja) サイクリン／ｃｄｋ複合体のリン酸化酵素活性測定方法
JP6840541B2 (ja) 修飾特異的バインダーを使用することによる分析物を分析するための方法
JP5524481B2 (ja) チロシンキナーゼリン酸化の測定方法
JP2008104356A (ja) リン酸化−脱リン酸化反応検出用基質群およびそれを用いた検出方法
US20110027809A1 (en) Method for evaluation of degree of malignancy of tumor cell
Lohi et al. Src phosphorylates EAST, a novel EGF receptor-associated protein
US20120282633A1 (en) Antibody specific to activated egfr
JP5514453B2 (ja) 発光タンパク質を用いたリン酸化酵素阻害物質のスクリーニング方法
JP2008539705A (ja) ＰＫＣθ阻害物質を同定するための細胞アッセイ法
Schwartz et al. Mechanisms and Components of the DNA Damage Checkpoint
Kaushansky Proteomic approaches to deciphering mechanisms of phosphotyrosine mediated signal transduction
HORBELT CONTEXT SPECIFIC SIGNALING OF TGF-β RECEPTOR II

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20050224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20051220

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060613